← Back to Search

Diagnostic Test

BVA-100 for Heart Failure

VA Boston Healthcare System, Boston, MA

BVA-100N/AWaitlist AvailableLed by Jacob JosephResearch Sponsored by Daxor Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up30 days post discharge

Awards & highlights

No Placebo-Only Group

Study Summary

This trial is testing whether using a machine to directly measure blood volume in addition to usual care results in more appropriate treatment and better patient outcomes.

Eligible Conditions

Acute Heart Failure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days post discharge

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days post discharge

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days post discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Quantitative assessment of progress to euvolemic target for both subjects and controls

Secondary outcome measures

Quantitative assessment of continuous outcome metrics: natriuretic peptide

Quantitative assessment of continuous outcome metrics: net fluid balance

Quantitative assessment of continuous outcome metrics: weight

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Standard care groupExperimental Treatment1 Intervention

Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will be blinded to the results and will choose between a low-moderate and high diuretic dose based on usual care clinical assessment of volume status.

Group II: BVA-guided treatment armExperimental Treatment1 Intervention

Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will receive the results and will choose between a low-moderate and high diuretic dose based on measured volume status.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BVA-100

2020

N/A

~90

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Daxor CorporationLead Sponsor

11 Previous Clinical Trials

235 Total Patients Enrolled

6 Trials studying Heart Failure

124 Patients Enrolled for Heart Failure

VA Boston Healthcare SystemFED

68 Previous Clinical Trials

970,478 Total Patients Enrolled

Minneapolis Veterans Affairs Medical CenterFED

69 Previous Clinical Trials

14,637 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently accepting participants for this experiment?

"According to clinicaltrials.gov, this trial is currently enlisting participants. The study was initiated on May 1st 2022 and modified in late July of the same year."

Answered by AI

How many participants are being recruited for this experiment?

"Affirmative, according to the information available on clinicaltrials.gov this medical trial is currently enlisting participants. This study was initially posted in May 1st 2022 and received a recent update at July 25th 2022; 32 research subjects need to be recruited from one site location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure

2022. "Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04855097.